OBJECTIVE: To study the efficacy of anti-miRNA-33 therapy on the progression of atherosclerosis. APPROACH AND RESULTS: Ldlr(-/-) mice were injected subcutaneously with PBS, control, or anti-miR-33 oligonucleotides weekly and fed a Western diet for 12 weeks. At the end of treatment, the expression of miR-33 target genes was increased in the liver and aorta, demonstrating effective inhibition of miR-33 function. Interestingly, plasma high-density lipoprotein (HDL)-cholesterol was significantly increased in anti-miR-33-treated mice but only when they were fed a chow diet. However, HDL isolated from anti-miR-33-treated mice showed an increase cholesterol efflux capacity compared with HDL isolated from nontargeting oligonucleotide-treated mice. Analysis of atherosclerosis revealed a significant reduction of plaque size and macrophage content in mice receiving anti-miR-33. In contrast, no differences in collagen content and necrotic areas were observed among the 3 groups. CONCLUSIONS: Long-term anti-miR-33 therapy significantly reduces the progression of atherosclerosis and improves HDL functionality. The antiatherogenic effect is independent of plasma HDL-cholesterol levels.
OBJECTIVE: To study the efficacy of anti-miRNA-33 therapy on the progression of atherosclerosis. APPROACH AND RESULTS:Ldlr(-/-) mice were injected subcutaneously with PBS, control, or anti-miR-33oligonucleotides weekly and fed a Western diet for 12 weeks. At the end of treatment, the expression of miR-33 target genes was increased in the liver and aorta, demonstrating effective inhibition of miR-33 function. Interestingly, plasma high-density lipoprotein (HDL)-cholesterol was significantly increased in anti-miR-33-treated mice but only when they were fed a chow diet. However, HDL isolated from anti-miR-33-treated mice showed an increase cholesterol efflux capacity compared with HDL isolated from nontargeting oligonucleotide-treated mice. Analysis of atherosclerosis revealed a significant reduction of plaque size and macrophage content in mice receiving anti-miR-33. In contrast, no differences in collagen content and necrotic areas were observed among the 3 groups. CONCLUSIONS: Long-term anti-miR-33 therapy significantly reduces the progression of atherosclerosis and improves HDL functionality. The antiatherogenic effect is independent of plasma HDL-cholesterol levels.
Authors: Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore Journal: J Clin Invest Date: 2011-06-06 Impact factor: 14.808
Authors: Isabelle Gerin; Laure-Alix Clerbaux; Olivier Haumont; Nicolas Lanthier; Arun K Das; Charles F Burant; Isabelle A Leclercq; Ormond A MacDougald; Guido T Bommer Journal: J Biol Chem Date: 2010-08-22 Impact factor: 5.157
Authors: Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader Journal: N Engl J Med Date: 2011-01-13 Impact factor: 91.245
Authors: S Hani Najafi-Shoushtari; Fjoralba Kristo; Yingxia Li; Toshi Shioda; David E Cohen; Robert E Gerszten; Anders M Näär Journal: Science Date: 2010-05-13 Impact factor: 47.728
Authors: Katey J Rayner; Yajaira Suárez; Alberto Dávalos; Saj Parathath; Michael L Fitzgerald; Norimasa Tamehiro; Edward A Fisher; Kathryn J Moore; Carlos Fernández-Hernando Journal: Science Date: 2010-05-13 Impact factor: 47.728
Authors: Stefano Tarantini; Cory B Giles; Jonathan D Wren; Nicole M Ashpole; M Noa Valcarcel-Ares; Jeanne Y Wei; William E Sonntag; Zoltan Ungvari; Anna Csiszar Journal: Age (Dordr) Date: 2016-08-26